AJCC Staging Eighth Edition
Melanoma Stage I and II Subgroups

N Category	T Category								
	Tis	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
N0	0	IA	IA	IB	IIA	IIA	IIB	IIB	IIC
5-Yr Survival		99%	97%		94%		87%		82%
10-Yr Survival		98%	94%		88%		82%		75%

Melanoma Stage III Subgroups

	T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
N1a	N/A	A	A	A	B	B	C	C	C
N1b	B	B	B	B	B	B	C	C	C
N1c	B	B	B	B	B	B	C	C	C
N2a	N/A	A	A	A	B	B	C	C	C
N2b	C	B	B	B	B	B	C	C	C
N2c	C	C	C	C	C	C	C	C	C
N3a	N/A	C	C	C	C	C	C	C	D
N3b	C	C	C	C	C	C	C	C	D
N3c	C	C	C	C	C	C	C	C	D

A = Stage IIIA	B = Stage IIIB	C = Stage IIIC	D = Stage IIID
5-Yr Survival	93%	83%	69%	32%
10-Yr Survival	88%	77%	60%	24%

Melanoma Institute Australia

EDUCATION

melanomaeducation.org.au

Primary tumour (T)

T0 No evidence of primary tumour

T1 ≤1.0 mm in thickness
- T1a: <0.8 mm; without ulceration
- T1b: <0.8 mm; with ulceration or
  0.8-1.0 mm; with or without ulceration

T2 >1.0-2.0 mm in thickness
- T2a: > 1.0-2.0 mm; without ulceration
- T2b: > 1.0-2.0 mm; with ulceration

T3 >2.0-4.0 mm in thickness
- T3a: >2.0-4.0 mm; without ulceration
- T3b: >2.0-4.0 mm; with ulceration

T4 >4.0 mm in thickness
- T4a: >4.0 mm; without ulceration
- T4b: >4.0 mm; with ulceration

Regional lymph nodes (N)

N1 1
- N1a: 1 clinically occult; no in transit/satellites
- N1b: 1 clinically detected; no in transit/satellites
- N1c: No regional lymph node disease; in transit/
  satellites present

N2 2 or 3
- N2a: 2 or 3 clinically occult; no in transit/satellites
- N2b: 2 or 3 (with ≥1 clinically detected);
  no in transit/satellites
- N2c: 1 clinically occult or clinically detected;
  in transit/satellites present

N3 ≥4
- N3a: ≥4 clinically occult; no in transit/satellites
- N3b: ≥4 (with ≥1 clinically detected) or the presence
  of any number of matted nodes; no in transit/
  satellites
- N3c: ≥2 clinically occult or clinically detected and/or
  presence of any number of matted nodes;
  in transit/satellites present

Gershenwald JE, Scolyer RA, Hess KR et al. CA: A Cancer Journal for Clinicians, 2017